Purpose: To compare the dosimetric impact and treatment delivery efficacy of phase-gated volumetric modulated arc therapy (VMAT) vs amplitude-gated VMAT for stereotactic body radiation therapy (SBRT) for lung cancer by using realistic three-dimensional-printed phantoms.
In gating approaches, the patient can breathe freely during the computed tomography (CT) scan and treatment. These techniques can be divided into two categories: phase gating and amplitude gating. In phase gating, the radiation beam is activated in a certain phase of the respiration cycle. In amplitude gating, the radiation beam is activated whenever a certain amplitude value is reached regardless of the phase in the patient's respiratory cycle. Amplitude gating is better at suppressing respiratory motion artifacts compared with phase gating. 5 One study has shown that an irregular breathing pattern could be the reason for poor dosimetric results in phasegated studies, and it could be a more significant issue with phase gating compared with amplitude gating. 6 In addition to the reasons mentioned above, amplitude gating may be more beneficial because amplitude gating has a shorter treatment time than phase gating.
Short treatment times are highly recommended for dose-delivery accuracy and delivery efficacy. Hoogeman et al. 7 observed that the displacement of the patient exceeded 1 mm within a 3 min time span. Kim et al. reported an average translational difference in the target position of 1.8 ± 1.0 mm and a total rotational misalignment of up to 6°in 40 min. 8 Similarly, Agazaryan et al. 9 found patient movement of up to 3 mm along each axis within a 5 min time span, despite patient immobilization.
Nonetheless, most of the clinically used gating techniques are time-based phase-gating methods. 4, 10, 11 Furthermore, several studies have compared the phase-and amplitude-gating methods by acquiring the four-dimensional (4D) CT image. To the best of our knowledge, no study has compared the dosimetric accuracy and delivery efficacy by generating a realistic patient-specific phantom model. [12] [13] [14] In this study, individualized lung phantoms were generated via a three-dimensional printer (3D EDISON, Lokit, Korea) to achieve realistic simulation, and VMAT lung SBRT treatment was delivered.
Gamma comparison was performed to evaluate the dosimetric accuracy of phase and amplitude gating, and the treatment time was compared by analyzing the trajectory log file to evaluate the treatment efficacy. Figure 1 shows the simplified flowchart of the comparison process between the phase-and amplitude-gated in dosimetric accuracy and the delivery efficacy.
| MATERIALS AND METHODS

2.A | Patient-specific 3D-printed respiratory lung phantoms
Four patients who had been treated by lung SBRT-gated VMAT were selected for this study. We attempted to reproduce various lung and tumor conditions, and Table 1 shows the detailed information of each patient.
Simplified flowchart of the comparison process between the phaseand amplitude-gated in dosimetric accuracy and the delivery efficacy.
Patient-specific lung phantoms that closely simulated the actual lung tissue and respiratory patterns of each patient were generated using 3D-printing techniques and respiratory breathing equipment.
The 3D-printed lung phantom was based on the end-of-exhale respiratory phase image from the 4D CT (LightSpeed RT16, GE healthcare, Chicago, IL) data using the Eclipse was produced with a mesh grid structure that was filled with 0.3 mm strips of 2 mm air gaps rather than an empty space to obtain a density similar to that of a real lung. 15 Fused deposition modeling with a 3D printer was used for phantom generation, and polylactic acid with 1.25 g/cm 3 density was used as the printing material.
2.B | Data acquisition
Respiratory motion data for approximately 4 min were obtained via
Varian's RPM system during a planned CT scan. It was continually repeated via QUASAR ™ phantom for the beam delivery. The patientspecific lung phantom was scanned using 4D CT with 1.25 mm slice thickness, and the RPM block was placed on the phantom (Fig. 3) .
The 4D CT images of each phantom with its respiratory pattern were reconstructed and sorted by phase-and amplitude-gating methods. The same CT was used for both gating methods.
For phase gating, the breathing cycle was evenly divided into 10 phases, and a 30% to 70% gating window was selected as patient treatment. For amplitude gating, the lower and upper thresholds of the selected amplitude range were defined from the 40% to 50%
gating window in the 10 phases used in phase gating of each patient. 16 An element of visual and/or verbal coaching could be used 
2.C | Analysis
To assess the dosimetric accuracy of phase-and amplitude-gated VMAT treatment, gamma analysis was performed using EBT3 film under the 2%/1 mm criterion with 80% passing rate. Many studies recommended a stricter gamma criterion of 2%/1 mm or 2%/2 mm rather than 3%/3 mm, particularly for VMAT quality assurance (QA).
However, 3%/3 mm was still an acceptable standard for evaluating IMRT and other plans in a clinical setting. [18] [19] [20] [21] The film images were scanned in 48-bit RGB (red, green, and blue) mode with 72 dpi resolution (pixel size: 0.35 mm) and were measured and analyzed using FilmQA pro 2012 software (Ashland Inc., Bridgewater, NJ, USA).
Delivery efficacy was also evaluated by analyzing the trajectory log file from the treatment records. The TrueBeam ™ control system generated a trajectory log file, which recorded the beam status data and various information about the expected and actual values of the treatment. By using this information, the following were evaluated: total treatment time, total time interval for the treatment, gate-on time, time interval when the gating system allowed the beam on, beam-on time, and time interval when the beam was delivered. Table 2 shows the results of gamma analysis under the 2%/1 mm criterion according to the phase-and amplitude-gating methods with patient-specific lung phantoms. There were noticeable differences in gamma passing rate according to the gating method. On average, the gamma passing rate of the amplitude gating was 5.2 ± 4.2% higher than the phase gating. Furthermore, it exceeded 80% in all cases, which was an acceptable passing rate under the 2%/1 mm criterion.
| RESULTS
3.A | Dosimetric accuracy
On the contrary, every case in phase gating, except for P4, did not exceed 80%. The 3%/3 mm criterion, which was generally recommended and routinely applied in clinical practice, showed similar average passing rates on both gating strategies (phase: 98.3;
amplitude: 98.7).
3.B | Delivery efficacy
In the phase-gating method shown in (86 and 99 s) faster than those in phase gating, respectively. Table 3 shows the summary of phase-and amplitude-gated VMAT deliveries, including the number of beam interruptions. According to this table, the average numbers of beam interruptions for the phase-and amplitude-gating methods were 39.5 and 0.5, respectively.
| DISCUSSION
The QA of gating systems should include an analysis of both the time delay and dosimetric characteristics of the gated delivery.
Thus, we compared the dosimetric impact and treatment delivery efficacy of phase-and amplitude-gated VMAT for stereotactic lung cancer treatment by using realistic patient-specific lung phantoms fabricated with a 3D printer. According to the results, there are noticeable differences between the two gating methods in terms of dosimetric accuracy. The average gamma passing rate of the amplitude gating was 5.2 ± 4.2% higher than the phase gating and in all cases exceeded 80%, which was an acceptable passing rate 
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